Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
biologic medication |
| gptkbp:administeredBy |
ribavirin
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2001 |
| gptkbp:ATCCode |
gptkb:L03AB10
|
| gptkbp:CASNumber |
198153-51-4
|
| gptkbp:contraindication |
autoimmune hepatitis
decompensated liver disease |
| gptkbp:developedBy |
gptkb:Schering-Plough
|
| gptkbp:drugClass |
interferons
|
| gptkbp:eliminationHalfLife |
40 hours
|
| gptkbp:form |
solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
peginterferon alfa-2b
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:PegIntron
|
| gptkbp:mechanismOfAction |
interferon alpha receptor agonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:product |
pegylated interferon alpha-2b
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:depression
gptkb:anemia fatigue neutropenia flu-like symptoms |
| gptkbp:UNII |
39R4TAN1VT
|
| gptkbp:usedFor |
gptkb:hepatitis_C
gptkb:hepatitis_B melanoma |
| gptkbp:bfsParent |
gptkb:PEG-INTRON
|
| gptkbp:bfsLayer |
6
|